Copper-Based Therapy Enhances Amyloid Clearance in Alzheimer’s Disease Models

Australian researchers have shown that a copper-based drug candidate can restore memory and significantly reduce toxic protein accumulation in mouse models of Alzheimer's disease. Rather than directly targeting amyloid plaques, the experimental therapy enhances the brain's natural waste-clearing system, offering a novel therapeutic strategy for the disease.

The compound, Cu(ATSM), is a copper-containing molecule that is already undergoing early-stage clinical evaluation for Parkinson's disease and amyotrophic lateral sclerosis (ALS). In the new study, scientists from Monash University and the University of Melbourne investigated whether the compound could improve the clearance of amyloid-beta (Aβ), one of the pathological hallmarks of Alzheimer's disease.

How Cu(ATSM) Works

Copper is an essential trace element involved in numerous neuronal processes, including energy production, antioxidant defense, and neurotransmission. In Alzheimer's disease, copper homeostasis appears to be disrupted, contributing to oxidative stress, neuroinflammation, neuronal dysfunction, and impaired clearance of toxic proteins.

Cu(ATSM) is designed to selectively deliver biologically available copper to affected tissues while exerting anti-inflammatory and neuroprotective effects. The researchers found that the compound increases the expression of P-glycoprotein (P-gp; ABCB1), an important transporter located within the blood-brain barrier (BBB) that actively exports amyloid-beta from the brain into the bloodstream.

Reduced expression and activity of P-gp have previously been associated with Alzheimer's disease, limiting amyloid-beta clearance and promoting its accumulation within brain tissue. By restoring P-gp function, the investigators aimed to enhance one of the brain's endogenous mechanisms for removing toxic proteins.

Findings From the Mouse Study

Transgenic mice with Alzheimer's-like pathology received Cu(ATSM) for 56 days before undergoing brain imaging and behavioral testing.

Treatment increased brain P-glycoprotein expression by 24.1%, suggesting successful restoration of the blood-brain barrier's amyloid clearance system.

The levels of particularly neurotoxic amyloid-beta species decreased by approximately 42% compared with untreated animals. In parallel, treated mice demonstrated nearly a 44% improvement in spatial memory performance, indicating better learning and memory function.

According to the researchers, these findings provide evidence that improving blood-brain barrier transport can simultaneously reduce amyloid-beta burden and improve cognitive performance in an Alzheimer's disease model. This is also the first study to demonstrate that Cu(ATSM) increases P-glycoprotein expression in this setting.

Safety Considerations and Clinical Translation

Although no obvious adverse effects were observed in the treated mice, the investigators detected increased systemic copper levels following treatment. These concentrations remained below known toxic thresholds, but the authors emphasize that comprehensive toxicology studies will be necessary before advancing to larger clinical trials.

Previous clinical experience with Cu(ATSM) also illustrates the challenges of translating encouraging preclinical findings into meaningful patient benefit. Early studies in amyotrophic lateral sclerosis (ALS) have not demonstrated significant clinical improvement, highlighting the importance of carefully designed clinical trials in Alzheimer's disease.

The researchers note that Alzheimer's disease is driven by multiple interconnected pathological processes—including amyloid-beta accumulation, tau pathology, chronic neuroinflammation, vascular dysfunction, oxidative stress, and synaptic degeneration. This complexity may partly explain why several amyloid-targeting therapies have produced only modest clinical benefits despite successfully reducing amyloid plaques.

Next Steps

Because previous clinical trials have demonstrated that reducing amyloid-beta burden can modestly slow cognitive decline in patients with early Alzheimer's disease, the current findings strengthen the rationale for evaluating Cu(ATSM) in human clinical trials involving individuals with early symptomatic disease.

Future studies will need to closely monitor copper metabolism, copper-dependent enzyme activity, oxidative stress biomarkers, and potential toxicity in organs such as the liver and kidneys.

The research team also plans to investigate how efficiently amyloid-beta is eliminated after entering the bloodstream and whether Cu(ATSM) could be combined with existing anti-amyloid monoclonal antibody therapies. Combining enhancement of the brain's natural clearance mechanisms with direct amyloid-targeting treatments may provide greater therapeutic benefit than either approach alone.

Overall, the study adds to growing evidence that restoring blood-brain barrier function and improving endogenous waste-clearance pathways may represent an important therapeutic strategy alongside direct removal of amyloid plaques. If these findings can be replicated in humans, Cu(ATSM) or related copper-based compounds could represent a promising new approach for the treatment of Alzheimer's disease.